Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference117 articles.
1. The next decade of immune checkpoint therapy;Sharma;Cancer Discov.,2021
2. Next-generation CAR T-cell therapies;Young;Cancer Discov.,2022
3. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies;Sullivan;Nat. Rev. Drug Discov.,2022
4. Economic sustainability of immune-checkpoint inhibitors: the looming threat;Verma;Nat. Rev. Clin. Oncol.,2018
5. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies;Galon;Nat. Rev. Drug Discov.,2019
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile;European Journal of Nuclear Medicine and Molecular Imaging;2024-07-15
2. Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides;Seminars in Nuclear Medicine;2024-07
3. Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity;Cell Reports Medicine;2024-05
4. Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing;Methods in Cell Biology;2024
5. Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery;Molecular Imaging and Biology;2023-10-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3